Aptadir's $45M seed ranks among Italy's largest health startup rounds

Milan-based biotech Aptadir Therapeutics has raised a $45M seed round, a raise the company describes as one of the largest early-stage funding rounds in Europe and one of the biggest ever closed by an Italian health startup.

The company is still at the preclinical stage. It is developing a novel class of RNA inhibitors — molecules used to silence defective genes — aimed at genetic conditions and underserved cancers. The underlying technology draws on the findings of an international group of scientists working across RNA and DNA biology, genetic disorders, leukaemia and immunotherapeutics. Aptadir's first programme targets Fragile X Syndrome, a genetic condition that causes intellectual disability, learning difficulties and developmental delays.

4BIO Capital, the London-based venture firm that invests in life sciences, led the round. Extend, Italy's national technology transfer hub for biotechnology and pharmaceuticals and an existing pre-seed investor in Aptadir, took part, alongside CDP Venture Capital, XGEN Venture and CE-Ventures.

The company said the funds will be used to advance its pipeline of therapeutics.

Giovanni Amabile, founder and CEO of Aptadir, framed the size of the round as a signal about the science: "The magnitude of this seed round reflects the exciting potential of our DiRs technology and the quality of a truly international scientific team. With the backing of our investors, we now have the opportunity to develop a pipeline of drug candidates with the potential to restore genetic pathways that, for decades, have been considered irreversibly silenced."

The deal lands in a corner of European venture where preclinical companies rarely command nine-figure-scale attention this early. Aptadir's pitch rests on RNA inhibition as a route into conditions that have resisted conventional drug development, starting with a syndrome for which no approved treatment exists. Whether the round's size translates into clinical progress will depend on how quickly the company can move its first candidate out of the lab — a step that, for a company at this stage, remains ahead of it.